# Ventus Therapeutics

> Structure-based drug discovery biotech using computational chemistry for small molecules.

## Why it is interesting

ReSOLVE platform targets 'undruggable' proteins — $140M Series C from SoftBank and RA Capital with a16z on cap table.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series C (Feb 2022): $140M co-led by SoftBank Vision Fund 2 and RA Capital; a16z participated (Ventus press)
- Co-investors not in VCT directory: SoftBank Vision Fund 2, RA Capital, GV, Versant Ventures
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/ventus-therapeutics